LANGHORNE, Pa., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced that it has signed a group purchasing agreement for regenerative skin grafting products with Premier, Inc. This agreement offers Premier alliance members access to Alliqua BioMedical's regenerative skin graft products, including Biovance® Human Amniotic Membrane Allograft, at specially negotiated pricing and terms.
Premier is a healthcare improvement company uniting an alliance of approximately 3,400 U.S. hospitals and 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.
"This award from Premier to Alliqua BioMedical in the category of Regenerative Skin Grafts is a milestone in the growth story of our company," said Brad Barton, Chief Operating Officer of Alliqua BioMedical. "As we strive to deliver a technological suite of solutions that allow wound care practitioners to manage acute and chronic wounds, our agreement with Premier will allow us to further extend our reach to hospitals and post-acute providers of care. Premier and Alliqua BioMedical are aligned with a focus on healthcare performance improvement - helping providers to realize clinical, financial and operational gains, so that they can sustainably serve the needs of their communities."
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
CONTACT: Investor Relations: Westwicke Partners on behalf of Alliqua Biomedical, Inc. Mike Piccinino, CFA +1-443-213-0500 AlliquaBiomedical@westwicke.com